Wiley announced the launch of eight new Advanced journals that will be available by the end of 2026, extending the Advanced brand into life, health and social sciences. The new titles will complement the existing portfolio of more than 25 high‑impact Advanced journals and are part of Wiley’s strategy to broaden the brand beyond its long‑standing focus on materials science.
The Advanced brand has been a trusted name for over 35 years, and the expansion follows the recent addition of Advanced Oncology, which opened for submissions in March 2026. Other recent additions include Advanced Intelligent Discovery and Advanced Robotics Research, added last year, and Advanced Chemical Engineering, which began accepting submissions last month. Wiley also co‑sponsors the MD Anderson Cancer and Neuroscience Symposium on February 19‑20 in Houston, underscoring its commitment to cutting‑edge research.
Wiley’s leadership explains that the move is designed to capture a larger share of the scientific publishing market and to provide researchers with prestigious yet accessible venues. Allyn Molina, group vice president of publishing development, said, "For more than 35 years, the Advanced brand has earned researchers' trust through rigorous standards and collaborative partnerships." He added, "Researchers have been telling us they need more prestigious yet accessible venues for their breakthrough work, and we listened; this expansion is our answer – launching premium options across every field of science."
The expansion aligns with Wiley’s broader focus on AI and open‑access growth. In its Q2 2026 earnings, Wiley reported revenue of $422 million, slightly below the $425 million forecast, but earnings per share of $1.10 beat the $1.00 expectation. The Research segment grew 6% in revenue, driven by AI licensing and open‑access initiatives, while the Learning segment declined 11% amid market softness. Management reaffirmed its fiscal 2026 outlook, maintaining an adjusted EBITDA margin target of 25.5%‑26.5% and an adjusted EPS range of $3.90‑$4.35, while narrowing revenue guidance to low‑single‑digit growth and increasing the share‑repurchase allocation to $100 million.
Kirsten Severing, editor‑in‑chief of Advanced Science, highlighted the editorial philosophy behind the expansion: "Our decades‑long legacy in the materials sciences has taught us the power of rigorous editorial standards combined with genuine collaboration. We're applying those same principles – quality, integrity, and interdisciplinary thinking – to these new fields. The goal is to make the Advanced Portfolio a natural home for researchers whose work crosses traditional boundaries." Matthew Kissner, president and CEO, emphasized the company’s momentum in AI and operational discipline: "We continue to deliver strong performance in Research and accelerating momentum in AI as we capitalize on record research volume and expanding corporate R&D opportunities... In AI, we are turning high‑value knowledge into impact through the execution of content licensing projects for large language models and corporate AI applications. Finally, operational excellence and margin expansion are a way of life for us as we continuously optimize our cost structure, drive investment and expense discipline, and advance our transformative publishing platform."
The expansion positions Wiley to compete more aggressively with other major scientific publishers such as Elsevier and Springer Nature. By leveraging its established Advanced brand, AI capabilities, and a streamlined editorial model that allows authors to submit once and be matched across journals, Wiley aims to increase article submissions, subscription revenue, and author‑funded open‑access income, thereby reinforcing its competitive moat in the global scientific publishing ecosystem.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.